Table 1 Patients characteristics
A | B | ||
|---|---|---|---|
N | 121 | N | 90 |
Age, years | 71 ± 12 | Age, years | 72 (63–78) |
Men, n (%) | 72 (60) | Men, n (%) | 54 (60) |
Serum phosphate (mg/dL) | 3.9 ± 1.1 | Serum phosphate (mg/dL) | 3.9 ± 1.1 |
eGFR (mL/min/1.73 m2)eGFR (mL/min/1.73 m2) | 20.2 (11.8–40.3) | eGFR (mL/min/1.73 m2)eGFR (mL/min/1.73 m2) | 21.3 (12–50.2) |
Log [eGFR] | 3.1 ± 0.8 | Log [eGFR] | 3.1 ± 0.8 |
Calcification Volume (mL) | 8.94 (3.26–18.9) | Calcification Volume (mL) | 8.0 (3.1–19.3) |
Calc/BSA (mL/m2)Calc/BSA (mL/m2) | 5.62 (2.01–12.7) | Calc/BSA (mL/m2)Calc/BSA (mL/m2) | 5.26 (1.96–13.2) |
Log [Calc/BSA] | 1.67 ± 1.20 | Log [Calc/BSA] | 1.66 (0.67–2.58) |
Systolic Blood Pressure (mmHg) | 134 ± 20 | Systolic Blood Pressure (mmHg) | 133 ± 20 |
Hypertension (n(%)) | 98 (81) | Hypertension (n(%)) | 69 (77) |
Diabetes mellitus (n (%)) | 54 (45) | Diabetes mellitus (n (%)) | 38 (42) |
Dyslipidemia (n (%)) | 69 (57) | Dyslipidemia (n (%)) | 49 (54) |
LDL-C (mg/dL) | 118 ± 66 | LDL-C (mg/dL) | 116 ± 65 |
Malignancy (n (%)) | 35 (29) | Malignancy (n (%)) | 30 (33) |
Medications | Medications | ||
Warfarin User (n (%)) | 14 (12) | Warfarin User (n (%)) | 12 (13) |
Vitamin D User (n (%)) | 12 (10) | Vitamin D User (n (%)) | 8 (9) |
Phosphate-Binding Agent User (n (%)) | 13 (11) | Phosphate-Binding Agent User (n (%)) | 8 (9) |
Diuretics user (n (%)) | 67 (55) | Diuretics user (n (%)) | 50 (56) |
ACEI/ARB User (n (%)) | 48 (40) | ACEI/ARB Duration | |
None or < 6 months (n (%)) | 42 (47) | ||
6 months ≤ < 2 years (n (%)) | 7 (8) | ||
2 years ≤ (n (%)) | 41 (46) | ||